Women with non-melanoma skin cancers more likely to have smoked cigarettes

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes & Control.

The study investigated the relationship between cigarette smoking and non-melanoma skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). Smoking histories were assessed and compared between patients diagnosed with BCC and/or SCC, and a group of controls comprised of patients who were screened for skin cancers, but who were not diagnosed with and had no history of skin cancer.

The study's 698 participants were recruited through Moffitt's Lifetime Screening and Prevention Center and the University of South Florida's Dermatology and Family Medicine Clinics. Participants were asked about their smoking behaviors in terms of years smoked, how many cigarettes per day they smoked, and when those who once smoked quit smoking. The results were stratified by sex.

Study results showed that cigarette smoking was associated with non-melanoma skin cancer overall, and that the risk increased with numbers of cigarettes per day, total years of smoking, and pack-years smoked. Associations were particularly strong for SCC, with SCC being more than two times as likely in those who have smoked for 20 or more years compared to controls.

"Among men, positive associations with smoking of equal magnitude were observed for BCC and SCC, although none of the associations were statistically significant," said Dana E. Rollison, Ph.D., study lead author and an associate member in the Moffitt Department of Cancer Epidemiology. "However, among women, smoking was not associated with BCC, while highly statistically significant associations were observed with SCC. Women with SCC were almost four times more likely than controls to have smoked for 20 or more years."

The researchers concluded that:

  • Cigarette smoking was associated with non-melanoma skin cancer, and the risk increased with increasing dose (cigarettes per day) and number of years smoked.
  • Among men, smoking was modestly associated with BCC and SCC.
  • Among women, smoking was strongly associated with SCC, but not BCC.

Why women smokers should be more likely than men to be diagnosed with SCC is not clear, said the researchers.

"Observations from the lung cancer literature may provide possible explanations for why smoking was a higher risk factor for SCC in women," wrote Rollison and co-authoring colleagues both at Moffitt and across USF's College of Medicine. "Female current smokers have higher lung cancer risks than men. Women have been shown to have more active CYP enzyme activity in the lung, where CYP is responsible for metabolizing 70-80 percent of nicotine. In addition, the up-regulation of CYP by estrogen may play a role."

Also, women have been shown to have higher levels of DNA adducts and lower levels of DNA repair in the lung as compared to men, said Rollison.

"Further study is needed to shed more light on the sex-based differences and the role of smoking in non-melanoma skin cancers," concluded Rollison.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease